J
Jonathan A. Ledermann
Researcher at University College London
Publications - 332
Citations - 28241
Jonathan A. Ledermann is an academic researcher from University College London. The author has contributed to research in topics: Ovarian cancer & Olaparib. The author has an hindex of 65, co-authored 300 publications receiving 21862 citations. Previous affiliations of Jonathan A. Ledermann include University College London Hospitals NHS Foundation Trust & University College Hospital.
Papers
More filters
Journal ArticleDOI
Biodistribution and tumour localisation of 131I SWA11 recognising the cluster w4 antigen in patients with small cell lung cancer.
TL;DR: It is shown that the biodistribution of radiolabelled SWA11 in man differs from human tumour xenograft models and that the antibody in unsuitable for targeting therapy to SCLC in man.
Journal ArticleDOI
Adverse events (AEs) with maintenance olaparib tablets in patients (pts) with BRCA-mutated (BRCAm) platinum-sensitive relapsed serous ovarian cancer (PSR SOC): Phase III SOLO2 trial.
Jonathan A. Ledermann,Alain Lortholary,Richard T. Penson,Emma Gibbs,Diane Provencher,Ilan Bruchim,Tomas Huzarski,Maria Pilar Barretina-Ginesta,Roberto Sabbatini,Linda R. Mileshkin,Nicoletta Colombo,Tjoung-Won Park-Simon,Koji Matsumoto,Gabe S. Sonke,Olga N. Mikheeva,Jae Weon Kim,Gustavo Girotto,Hannelore Denys,Elizabeth S. Lowe,Eric Pujade-Lauraine +19 more
TL;DR: maintenance therapy with the PARP inhibitor olaparib significantly improved PFS vs placebo (PBO) in BRCAm PSR SOC pts (HR 0.30, 95% CI...
Journal ArticleDOI
Lessons learned from a decade of clinical trials of high-dose chemotherapy in ovarian cancer
TL;DR: Five randomized trials of high-dose chemotherapy in ovarian cancer have been conducted and all experienced difficulty in recruitment, as well as some of the lessons that have been learned about HDC in solid tumors in the last decade.
Journal ArticleDOI
SCOTROC 2B: feasibility of carboplatin followed by docetaxel or docetaxel–irinotecan as first-line therapy for ovarian cancer
Andrew R Clamp,Johanna Mäenpää,Derek Cruickshank,Jonathan A. Ledermann,Peter M Wilkinson,Richard Welch,Steve Chan,Paul Vasey,B Sorbe,A C Hindley,Gordon C Jayson +10 more
TL;DR: The addition of irinotecan to first-line carboplatin and docetaxel chemotherapy was generally well tolerated although associated with increased gastrointestinal toxicity and further exploratory studies of topoisomerase-I inhibitors in this setting may be warranted.
Journal ArticleDOI
New clinical research strategies for rare gynecologic malignancies.
TL;DR: Harmonization of medical practices and novel trial designs are needed to identify and develop new treatments for rare gynecologic tumors and this requires international partnerships, harmonization of treatment recommendations, and international collaborations to overcome existing regulatory barriers in international trials.